Cumberland Pharmaceuticals annual operating expenses
2009
2010
2011
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cumberland Pharmaceuticals Operating Expenses Growth & History (CPIX)
Cumberland Pharmaceuticals's operating expenses was $40.6M for fiscal 2025.
View full Cumberland Pharmaceuticals company overviewCumberland Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $40.6M | $2.9M | +7.77% |
| 2024 | 2024-12-31 | $37.7M | −$5.3M | −12.37% |
| 2023 | 2023-12-31 | $43.0M | $4.4M | +11.51% |
| 2022 | 2022-12-31 | $38.6M | $4.7M | +13.82% |
| 2021 | 2021-12-31 | $33.9M | $342,183 | +1.02% |
| 2020 | 2020-12-31 | $33.6M | −$705,463 | −2.06% |
| 2019 | 2019-12-31 | $34.3M | $314,576 | +0.93% |
| 2018 | 2018-12-31 | $34.0M | −$3.1M | −8.43% |
| 2017 | 2017-12-31 | $37.1M | $9.1M | +32.68% |
| 2016 | 2016-12-31 | $28.0M | — | — |
| 2011 | 2011-12-31 | $35.9M | $142,757 | +0.40% |
| 2010 | 2010-12-31 | $35.8M | $2.2M | +6.44% |
| 2009 | 2009-12-31 | $33.6M | — | — |
Cumberland Pharmaceuticals quarterly operating expenses
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | −$8.6M | −72.15% |
| Q1 2026 | 2026-03-31 | $10.3M | $1.3M | +14.80% |
| Q4 2025 | 2025-12-31 | $10.4M | $135,333 | +1.31% |
| Q3 2025 | 2025-09-30 | $9.3M | −$188,383 | −1.99% |
| Q2 2025 | 2025-06-30 | $11.9M | $2.8M | +30.34% |
| Q1 2025 | 2025-03-31 | $9.0M | $203,985 | +2.32% |
| Q4 2024 | 2024-12-31 | $10.3M | −$3.7M | −26.43% |
| Q3 2024 | 2024-09-30 | $9.5M | −$729,694 | −7.16% |
| Q2 2024 | 2024-06-30 | $9.2M | −$180,651 | −1.93% |
| Q1 2024 | 2024-03-31 | $8.8M | −$714,643 | −7.52% |
| Q4 2023 | 2023-12-31 | $14.0M | $5.3M | +60.01% |
| Q3 2023 | 2023-09-30 | $10.2M | $709,722 | +7.49% |
| Q2 2023 | 2023-06-30 | $9.3M | −$768,562 | −7.60% |
| Q1 2023 | 2023-03-31 | $9.5M | −$749,107 | −7.30% |
| Q4 2022 | 2022-12-31 | $8.8M | $342,345 | +4.07% |
| Q3 2022 | 2022-09-30 | $9.5M | $1.2M | +14.07% |
| Q2 2022 | 2022-06-30 | $10.1M | $1.4M | +15.58% |
| Q1 2022 | 2022-03-31 | $10.3M | $1.8M | +21.45% |
| Q4 2021 | 2021-12-31 | $8.4M | $267,829 | +3.29% |
| Q3 2021 | 2021-09-30 | $8.3M | −$8,628 | −0.10% |
| Q2 2021 | 2021-06-30 | $8.8M | $181,406 | +2.12% |
| Q1 2021 | 2021-03-31 | $8.4M | −$98,424 | −1.15% |
| Q4 2020 | 2020-12-31 | $8.1M | −$188,908 | −2.27% |
| Q3 2020 | 2020-09-30 | $8.3M | −$234,689 | −2.74% |
| Q2 2020 | 2020-06-30 | $8.6M | −$429,417 | −4.77% |
| Q1 2020 | 2020-03-31 | $8.5M | $147,551 | +1.76% |
| Q4 2019 | 2019-12-31 | $8.3M | — | — |
| Q3 2019 | 2019-09-30 | $8.6M | −$287,725 | −3.26% |
| Q2 2019 | 2019-06-30 | $9.0M | −$510,809 | −5.37% |
| Q1 2019 | 2019-03-31 | $8.4M | −$1.1M | −11.74% |
| Q3 2018 | 2018-09-30 | $8.8M | −$1.0M | −10.45% |
| Q2 2018 | 2018-06-30 | $9.5M | $830,311 | +9.57% |
| Q1 2018 | 2018-03-31 | $9.5M | $598,806 | +6.72% |
| Q4 2017 | 2017-12-31 | $9.6M | — | — |
| Q3 2017 | 2017-09-30 | $9.9M | $3.2M | +47.58% |
| Q2 2017 | 2017-06-30 | $8.7M | $2.3M | +36.36% |
| Q1 2017 | 2017-03-31 | $8.9M | $1.9M | +27.07% |
| Q3 2016 | 2016-09-30 | $6.7M | $53,685 | +0.81% |
| Q2 2016 | 2016-06-30 | $6.4M | −$633,926 | −9.06% |
| Q1 2016 | 2016-03-31 | $7.0M | −$506,641 | −6.74% |
| Q3 2015 | 2015-09-30 | $6.6M | −$766,298 | −10.35% |
| Q2 2015 | 2015-06-30 | $7.0M | −$236,934 | −3.27% |
| Q1 2015 | 2015-03-31 | $7.5M | $889,341 | +13.41% |
| Q3 2014 | 2014-09-30 | $7.4M | $387,886 | +5.53% |
| Q2 2014 | 2014-06-30 | $7.2M | $168,944 | +2.39% |
| Q1 2014 | 2014-03-31 | $6.6M | −$1.2M | −15.24% |
| Q3 2013 | 2013-09-30 | $7.0M | −$1.6M | −18.75% |
| Q2 2013 | 2013-06-30 | $7.1M | −$2.3M | −24.21% |
| Q1 2013 | 2013-03-31 | $7.8M | −$938,201 | −10.71% |
| Q3 2012 | 2012-09-30 | $8.6M | $16,032 | +0.19% |
| Q2 2012 | 2012-06-30 | $9.3M | −$150,720 | −1.59% |
| Q1 2012 | 2012-03-31 | $8.8M | $289,659 | +3.42% |
| Q4 2011 | 2011-12-31 | $9.4M | — | — |
| Q3 2011 | 2011-09-30 | $8.6M | −$222,917 | −2.52% |
| Q2 2011 | 2011-06-30 | $9.5M | $608,374 | +6.86% |
| Q1 2011 | 2011-03-31 | $8.5M | — | — |
| Q3 2010 | 2010-09-30 | $8.8M | — | — |
| Q2 2010 | 2010-06-30 | $8.9M | — | — |
Cumberland Pharmaceuticals operating expenses trends
Over the last five fiscal years, Cumberland Pharmaceuticals's operating expenses increased from $33.6M to $40.6M, a change of $7.1M. The latest reported quarter, Q2 2026, shows $3.3M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cumberland Pharmaceuticals source filings ↗Community posts
Cumberland’s sclerosis study supports safety but cannot establish efficacy
Cumberland Pharmaceuticals ($CPIX) reported results from its 12-month ASSIST-SSc pilot study of oral ifetroban in systemic sclerosis. Thirty-one participants received the drug and ten received placebo. The company described tolerability as ...
